Mrinal Kanti bhoumik

Mrinal Kanti bhoumik

Researcher

Jubilant Cadista Pharmaceutical Inc

Profile ID RP-003-8541 Joined 2026-02-23 1 article
0Connections
4
Total Views
1
Total Publications
30
Publication Views

About me

Pharmaceutical formulation and process development expert with strategic and hands-on experience in advanced formulation, process and analytical development, encompassing immediate release, orally Disintegrating Tablets (ODTs), complex multiparticulate systems, modified-release platforms for tablets, capsules, and other dosage forms. Specialized in formulation design, scale-up, and technology transfer across clinical and commercial settings. Proficient in Quality by Design (QbD), Process Analytical Technology (PAT), and CMC development. Proven track record in regulatory documentation for ANDA and PAS submissions. Passionate about data-driven, translational research that bridges lab innovation with industrial application.

Articles(1)

Authors: , Vinod Kumar Kondreddy, Rishav, , D. R. Nagesh, , Deepika Saini, , C. Kavitha, , Mrinal Kanti Bhoumik, , Reena Sharma, , Ramanlal N. Kachave, , M. Vishala

DOI: 10.51470/bca.2025.25.2.1987

Volume25
Issue2
Pages1987-1993
Abstract

The objective of this research is to create and validate an analytical method for the RP-HPLC estimation of telmisartan and hydrochlorothiazide. The HPLC Binary Gradient System (HPLC 3000 series) was used to construct the analytical procedure. The column used was the Cosmosil C18, which had dimensions of 250mm x 4.ID and a particle size of 5µm. The mobile phase consisted of a 60:40 mixture of methanol and water, and the flow rate was 0.8 ml. The detected wavelength was 231nm. The half-life of hydrochlorothiazide was 5.5 minutes and that of telmisartan was 4.1 minutes. Two drugs, telmisartan and hydrochlorothiazide, were determined to have linearities of 0.998 and 0.999, respectively. The % recovery for Hydrochlorothiazide was 99.71% and the limit of detection for Telmisartan was 0.174, whereas for Hydrochlorothiazide it was 0.339. This method was created with accuracy, simplicity, precision and cost-effectiveness in mind. The approach provides precise estimations of hydrochlorothiazide and telmisartan.

No matching articles

Try another word from the title, author or DOI.

Brief Bio

Pharmaceutical formulation and process development expert with strategic and hands-on experience in advanced formulation, process and analytical development, encompassing immediate release, orally Disintegrating Tablets (ODTs), complex multiparticulate systems, modified-release platforms for tablets, capsules, and other dosage forms. Specialized in formulation design, scale-up, and technology transfer across clinical and commercial settings. Proficient in Quality by Design (QbD), Process Analytical Technology (PAT), and CMC development. Proven track record in regulatory documentation for ANDA and PAS submissions. Passionate about data-driven, translational research that bridges lab innovation with industrial application.

Affiliations

Nothing added yet.

Education

Nothing added yet.

Honors & Awards

Nothing added yet.

Society Memberships

Nothing added yet.

Expertise

Nothing added yet.

Specialty

Nothing added yet.

Other Online Pages

Scholars in the same field

SN
Soumya Nayak
0 publications
Jinu Sudhakaran
Kookmin University
6 publications
CM
Carol Mary Koshy
0 publications
VS
Vinny Sharma
0 publications
ZB
Zenish Bhatti
0 publications
YS
yatakona supriya
0 publications
HP
Himanshu Pandey
0 publications
J
jgjgg
adada
0 publications
П
Павло
https://orcid.org/0000-0002-7760-9610
0 publications

Following

Nobody here yet.

Followers

Nobody here yet.

1 Publications